L
Lixte Biotechnology Holdings, Inc. (LIXT)
NCM – Real Time Price. Currency in USD
5.07
-0.08 (-1.55%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.07
-0.08 (-1.55%)
At close: May 12, 2026, 4:00 PM EDT
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
| Name | Position |
|---|---|
| Mr. Bastiaan van der Baan M.Sc. | Chief Scientific Officer |
| Mr. Geordan G. Pursglove | CEO, President & Chairman |
| Mr. Peter M. Stazzone | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-17 | 8-K | form8-k.htm |
| 2026-03-31 | 10-K | form10-k.htm |
| 2026-03-20 | 8-K | form8-k.htm |
| 2026-03-10 | 8-K | form8-k.htm |
| 2026-02-18 | 8-K | form8-k.htm |
| 2025-12-31 | 8-K | form8-k.htm |
| 2025-12-23 | 8-K | form8-k.htm |
| 2025-12-22 | 8-K | form8-k.htm |
| 2025-12-11 | 8-K | form8-k.htm |
| 2025-11-25 | 8-K | form8-k.htm |